Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15606 | 0.83 | GRIK1 (0.42) | GRIK1ALDH1A1KDM4ELMNAATM | |
| SCHEMBL15607 | 0.83 | GRIK1 (0.42) | GRIK1ALDH1A1KDM4ELMNAATM | |
| SCHEMBL7563918 | 0.83 | GRIK1 (0.42) | GRIK1ALDH1A1KDM4ELMNAATM | |
| SCHEMBL28312635 | 0.82 | EGFR (0.41) | GRIK1ALDH1A1TDP1CYP2C9KDM4E | |
| SCHEMBL27365320 | 0.80 | GRIK1 (0.33) | GRIK1CYP2C9 | |
| SCHEMBL5644185 | 0.79 | ADORA2A (0.37) | GRIK1ALDH1A1TDP1CYP2C9KDM4E | |
| SCHEMBL15688613 | 0.79 | ADORA2A (0.37) | GRIK1ALDH1A1TDP1CYP2C9KDM4E | |
| SCHEMBL31126660 | 0.76 | ALDH1A1 (0.46) | ALDH1A1TDP1CYP2C9KDM4ELMNA | |
| SCHEMBL1419493 | 0.76 | CYP2C9 (0.56) | ALDH1A1TDP1CYP2C9KDM4ELMNA | |
| SCHEMBL1419495 | 0.76 | CYP2C9 (0.56) | ALDH1A1TDP1CYP2C9KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462738-B2 | Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-09 | — | — | US | disclosed |
| US-20080026433-A1 | Use of enzymatic resolution for the preparation of intermediates of pregabalin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-31 | — | — | US | disclosed |
| US-20070293694-A1 | Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293694-A1 | Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof | RIMKLA, GABRE, GRIK5 | GRIK1 51/4885ALDH1A1 1872/4885TDP1 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.